SCHEMBL97372

SCHEMBL97372

[CH2]c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.53
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
ELANE P08246 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
STAT3 P40763 2/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
SLC7A5 Q01650 1/20 0.39
ALOX15 P16050 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28223436 0.93 CA12 (0.47) CA12CA1CA2CA9CA14
SCHEMBL109451 0.89 CA1 (0.61) CA12CA1CA2CA9CA14
Hydrazine SCHEMBL10771056 0.85 CA12 (0.62) CA12CA1CA2CA9CA14
SCHEMBL7346783 0.83 CA12 (0.53) CA12CA1CA2CA9CA14
SCHEMBL6350965 0.83 CA12 (0.71) CA12CA1CA2CA9CA14
SCHEMBL4532351 0.83 ELANE (0.60) CA12CA1CA2CA9CA14
SCHEMBL7588242 0.82 CA1 (0.49) CA12CA1CA2CA9CA14
Ethylene SCHEMBL27622376 0.82 CA12 (0.55) CA12CA1CA2CA9CA14
SCHEMBL9311265 0.82 CA12 (0.51) CA12CA1CA2CA9CA14
SCHEMBL7346788 0.81 CA1 (0.59) CA12CA1CA2CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230014840-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND NIPPON SHINYAKU CO., LTD. (JP) 2023-01-19 US claimed
US-20230018780-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND NIPPON SHINYAKU CO., LTD. (JP) 2023-01-19 US claimed
CN-114981281-A Method for producing oligonucleotide compound 日本新药株式会社 2022-08-30 CN claimed
WO-2021095875-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND 日本新薬株式会社 2021-05-20 WO claimed
WO-2021095874-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND 日本新薬株式会社 2021-05-20 WO claimed
US-5356888-A Elastase inhibitors FARMITALIA CARLO ERBA (IT) 1994-10-18 US claimed
EP-0505413-B1 BETA-LACTAM DERIVATIVES ERBA CARLO SPA (IT) 1994-08-31 EP claimed
EP-0378604-B1 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES ERBA CARLO SPA (IT) 1994-03-02 EP claimed
EP-0505413-A1 BETA-LACTAM DERIVATIVES. ERBA FARMITALIA (IT) 1992-09-30 EP claimed
WO-1991009036-A1 BETA-LACTAM DERIVATIVES FARMITALIA CARLO ERBA S.R.L. (IT) 1991-06-27 WO claimed
EP-0378604-A1 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES. ERBA CARLO SPA (IT) 1990-07-25 EP claimed
WO-1989010926-A1 1,1-DIOXO-CEPHEM-4-CARBOTHIOLIC ACID DERIVATIVES FARMITALIA CARLO ERBA S.R.L. (IT) 1989-11-16 WO claimed
US-4181733-A ANTIBIOTICS MERCK & CO., INC. (US) 1980-01-01 US claimed
EP-4400168-A2 ANTISENSE NUCLEIC ACIDS Nippon Shinyaku Co., Ltd. (JP) 2024-07-17 EP disclosed
CN-112384520-B Method for producing oligonucleotide compound 日本新药株式会社 2024-06-11 CN disclosed
CN-118109468-A Antisense nucleic acid to induce skipping of exon 50 日本新药株式会社 2024-05-31 CN disclosed
US-4172144-A Schiff's base derivatives of thienamycin MERCK & CO., INC. (US) 1979-10-23 US disclosed
US-4150145-A ANTIBIOTIC, BACTERICIDES MERCK & CO., INC. (US) 1979-04-17 US disclosed
EP-0001264-A1 Substituted N-methylene derivatives of thienamycin sulfoxide and sulfone and their preparation MERCK & CO. INC. (US) 1979-04-04 EP disclosed
EP-0001265-A1 O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds MERCK & CO. INC. (US) 1979-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230018780-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND POLRMT, POLR2H, POLM CA12 2885/4885CA1 538/4885CA2 467/4885
US-20230014840-A1 METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND DNASE1, XRN2, FBL CA12 1173/4885CA1 405/4885CA2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.